Our results identified predictive factors for pCR in HER2+ BC subtype across different HER2+ categories, revealing that HER2 IHC 3+ tumors had a more frequent tumoral and lymph nodal pCR, 93.7% and 86.7% respectively, compared to IHC 2+/SISH+. Here, ERBB2 is linked to breast cancer.